Literature DB >> 34129898

Niujiaodihuang Detoxify Decoction inhibits ferroptosis by enhancing glutathione synthesis in acute liver failure models.

Yichun Ji1, Wenwen Si2, Juan Zeng3, Liqiao Huang4, Zifeng Huang2, Lijun Zhao2, Jiahui Liu5, Meiling Zhu6, Weihong Kuang7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Niujiaodihuang Detoxify Decoction (NDD) is an integrated traditional Chinese medicine prescription that has been used as a therapeutic agent for the treatment of acute liver failure (ALF). However, the mechanisms underlying its action remain unclear. AIM OF THE STUDY: To determine the protective effect of NDD on D-galactosamine/lipopolysaccharide (D-GalN/LPS)-induced ALF and explore the underlying mechanisms.
MATERIALS AND METHODS: We characterized the NDD fingerprint by HPLC and established D-GalN/LPS-induced ALF models in Sprague-Dawley rats and LO2 cells. Next, we measured the protective and antiferroptotic effects of NDD in vivo and in vitro. To further investigate the molecular mechanisms underlying the effects of NDD, we performed metabolomic analysis of the liver tissue using LC-MS/MS.
RESULTS: Results of serum biochemical analysis, liver histopathology, and cell viability showed that NDD effectively relieved the liver injury. It reduced the accumulation of labile iron and alleviated lipid peroxidation by enhancing GPX4 activity. The mitochondrial morphology indicated that NDD exerted its hepatoprotective effect through an antiferroptotic activity. Metabolomic analysis showed that NDD treatment increased the levels of cysteine, decreased those of glutamate, and ameliorated the D-GalN/LPS-induced reduction in the levels of glutathione (GSH). The results for intracellular levels of reduced (GSH) and oxidized (GSSG) glutathione were consistent with those of metabolomic analysis.
CONCLUSION: Our findings indicate that NDD exerts hepatoprotective activity by evoking the reprogramming of GSH metabolism, and thereby, inhibiting ferroptosis.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute liver failure; Ferroptosis; GSH metabolism; Niujiaodihuang detoxify decoction

Mesh:

Substances:

Year:  2021        PMID: 34129898     DOI: 10.1016/j.jep.2021.114305

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Clinical Study of 2 Radiotherapy Techniques for Semi-Hepatic Alternating Radiotherapy on Diffuse Liver Metastasis in Patients with Breast Cancer.

Authors:  Jiangzhou Zhang; Shuheng Bai; Xingzhou Zhang; Yanli Yan; Haojing Kang; Guangzu Li; Zhaode Feng; Wen Ma; Hong Sun; Juan Ren
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

2.  Oyster-Derived Tyr-Ala (YA) Peptide Prevents Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Failure by Suppressing Inflammatory, Apoptotic, Ferroptotic, and Pyroptotic Signals.

Authors:  Adrian S Siregar; Marie Merci Nyiramana; Eun-Jin Kim; Soo Buem Cho; Min Seok Woo; Dong Kun Lee; Seong-Geun Hong; Jaehee Han; Sang Soo Kang; Deok Ryong Kim; Yeung Joon Choi; Dawon Kang
Journal:  Mar Drugs       Date:  2021-10-28       Impact factor: 5.118

3.  Hepatic TGFβr1 Deficiency Attenuates Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Failure Through Inhibiting GSK3β-Nrf2-Mediated Hepatocyte Apoptosis and Ferroptosis.

Authors:  Sha Huang; Yuhua Wang; Shuwen Xie; Yuqi Lai; Chan Mo; Ting Zeng; Shanshan Kuang; Guanghui Deng; Chuying Zhou; Yuyao Chen; Shaohui Huang; Lei Gao; Zhiping Lv
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-02-21

4.  Maresin1 Protect Against Ferroptosis-Induced Liver Injury Through ROS Inhibition and Nrf2/HO-1/GPX4 Activation.

Authors:  Wenchang Yang; Yaxin Wang; Chenggang Zhang; Yongzhou Huang; Jiaxian Yu; Liang Shi; Peng Zhang; Yuping Yin; Ruidong Li; Kaixiong Tao
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

Review 5.  The Regulatory Effects of Traditional Chinese Medicine on Ferroptosis.

Authors:  Qian Gao; Xue-Dong Yin; Fan Zhang; Yi-Zhun Zhu; Zhi-Ling Li
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.